RadNet

RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The firm offers magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures. RadNet was founded by Howard G. Berger in 1980 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

RadNet reports strong Q4 earnings, targets AI growth in 2023

RadNet's Q4 2022 performance demonstrated strong revenue and EBITDA growth, fueled by procedural demand and strategic investments in AI and expansion initiatives.
Despite challenges like labor market disruptions and a net loss, the company's focus on innovation, market positioning, and financial discipline bodes well for future profitability and growth.
Opportunities lie in AI revenue growth, de novo center profitability, and market expansion, positioning RadNet as a key player in the radiology industry with a clear path to sustained success.
With a commitment to quality services, shareholder value, and operational excellence, RadNet's strategic vision aligns with industry trends and growth opportunities, setting the stage for continued success and market leadership.

RadNet reports record Q1 revenue and EBITDA growth, eyes AI expansion

RadNet's Q1 2023 showcased strong financial performance and operational improvements. Despite challenges like net loss and labor inflation, the company is strategically positioned for growth through expansion and AI initiatives. Opportunities in advanced imaging services and cancer detection technologies present avenues for future success.

RadNet reports record Q2 earnings, eyes growth amid challenges

RadNet's Q2 2023 performance reflects strong revenue and EBITDA growth, driven by core Imaging Center segment.
While facing challenges like potential Medicare cuts and AI segment delays, the company is optimistic about growth opportunities.
Strategic initiatives in preventative medicine, AI, and outpatient services position RadNet for future success.
With a focus on innovation and financial strength, RadNet aims to capitalize on market shifts and technological advancements.

RadNet reports robust Q3 earnings, eyes growth through AI and partnerships

RadNet's Q3 performance reflects strong revenue growth and financial management, supported by AI division success and strategic initiatives for 2024.
Despite challenges such as staffing shortages and pricing discussions, the company's strengths in liquidity, debt management, and operational focus position it well for future growth.
Opportunities in acquisitions, AI investments, and partnerships offer avenues for expansion and innovation, driving RadNet's market leadership and service excellence.
Overall, RadNet's focus on growth, efficiency, and strategic partnerships underscores its commitment to sustainable success and market resilience in the healthcare industry.

RadNet reports record Q4 earnings, eyes AI growth opportunities

RadNet's Q4 2023 performance was strong, with record revenue and adjusted EBITDA driven by Imaging Center segment growth.
The company's focus on AI, acquisitions, and joint ventures presents growth opportunities but also challenges in reaching expansion targets.
Management's commitment to market leadership and financial strength positions RadNet well for future success and innovation.
RadNet's strategic investments and balance sheet strength support its growth initiatives and potential breakthroughs in AI solutions.

RadNet achieves record Q3 results, eyes AI growth opportunities

RadNet's Q3 2024 performance showcased exceptional financial results, underpinned by revenue growth, operational efficiency, and strategic guidance revisions for the full year.
The company's strengths lie in expansion initiatives, innovative collaborations, and a forward-looking approach towards technology commercialization and digital health advancement.
While facing challenges in regional adoption rates and program implementations, RadNet is well-positioned to capitalize on opportunities through strategic partnerships, AI profitability, and market expansion efforts.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RadNet (RDNT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes RadNet (RDNT) a New Buy Stock

RadNet (RDNT) is optimistic about maintaining momentum on several positive developments.

RadNet Hits New 52-Week High: What's Driving the Stock?

Shares pop after news breaks that the company is joining an index. Here are the key details for investors.

Why RadNet Is Shooting Higher Today

RadNet, Inc. (RDNT) CEO Howard Berger on Q3 2019 Results - Earnings Call Transcript

RadNet (RDNT) delivered earnings and revenue surprises of -27.27% and 2.70%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

RadNet (RDNT) Lags Q3 Earnings Estimates

LOS ANGELES, Nov.  07, 2019  (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services today reported it has created a multifaceted partnership with Whiterabbit.ai utilizing artificial intelligence, other technologies and operational protocols to address solutions for breast cancer imaging.

RadNet and Whiterabbit.ai Form a Comprehensive Partnership to Address Mammography Compliance and Improved Diagnostics for Breast Cancer

RadNet (RDNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RadNet (RDNT) Earnings Expected to Grow: Should You Buy?

LOS ANGELES, Sept.  24, 2019  (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:  RDNT ), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company Fall 2019 Conference on Wednesday, September 25th in New York, NY at 1:35 p.m. Eastern Time. 

RadNet, Inc. to Present at the Sidoti & Company Fall 2019 Conference on Wednesday, September 25th

Improves the ability to diagnose neurological conditions. Improves the ability to diagnose neurological conditions.

Delaware Imaging Network Offers New Brain Imaging Software in Delaware

RadNet, Inc. (RDNT) CEO Howard Berger on Q2 2019 Results - Earnings Call Transcript

RadNet (RDNT) delivered earnings and revenue surprises of -16.67% and 6.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

RadNet (RDNT) Q2 Earnings Lag Estimates

BioSpecifics Technologies

Cantel Medical

Champions Oncology

TransEnterix

In the long-run, does consistent market timing really matter to be a successful investor?

Simple Market Timing Strategies That Work - August 05, 2019

RadNet, Inc. (RDNT) CEO Howard Berger on Q1 2019 Results - Earnings Call Transcript

Earnings Preview: RadNet (RDNT) Q1 Earnings Expected to Decline

RadNet, Inc. (RDNT) CEO Howard Berger on Q4 2018 Results - Earnings Call Transcript

News for RadNet Stock (RDNT)